FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790951009> ?p ?o ?g. }

• W2790951009 endingPage "948" @default.
• W2790951009 startingPage "940" @default.
• W2790951009 abstract "Patients with previous atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) are at high risk of future cardiovascular events. Despite maximally tolerated doses of statins, many patients still have elevated low-density lipoprotein cholesterol (LDL-C) levels. We evaluated the efficacy and safety of alirocumab in patients with ASCVD and/or HeFH on a maximally tolerated dose of statin (rosuvastatin 20 or 40 mg, atorvastatin 40 or 80 mg, or simvastatin 80 mg, or lower doses with an investigator-approved reason) ± other lipid-lowering therapies from 5 placebo-controlled phase 3 trials (52 to 78 weeks). Patients with (n = 2,449) and without (n = 1,050) ASCVD were pooled from the FH I, FH II, HIGH FH, LONG TERM, and COMBO I trials. Patients with HeFH with (n = 575) and without ASCVD (n = 682) were pooled from all trials except COMBO I. High-intensity statins were utilized in 55.7% to 59.0% and in 72.4% to 87.6% of the ASCVD and the HeFH groups, respectively. Efficacy end points included LDL-C percent change from baseline to week 24 stratified by alirocumab dose. Mean baseline demographics and lipid levels were comparable in alirocumab- and placebo-treated patients. LDL-C reductions from baseline at week 24 ranged from 46.6% to 51.3% for alirocumab 75/150 mg and from 54.1% to 61.9% for alirocumab 150 mg in ASCVD and HeFH groups and were sustained for up to 78 weeks. LDL-C reductions with alirocumab were independent of ASCVD and/or HeFH status (interaction p value >0.05). Concordant results were observed for other lipids analyzed. The overall safety in the subgroups analyzed was similar in both treatment arms. Injection-site reactions were observed more frequently with alirocumab versus placebo." @default.
• W2790951009 created "2018-03-29" @default.
• W2790951009 creator A5003094687 @default.
• W2790951009 creator A5003747242 @default.
• W2790951009 creator A5008382551 @default.
• W2790951009 creator A5009467334 @default.
• W2790951009 creator A5032598384 @default.
• W2790951009 creator A5052604218 @default.
• W2790951009 creator A5055380940 @default.
• W2790951009 creator A5064108235 @default.
• W2790951009 creator A5066931153 @default.
• W2790951009 date "2018-04-01" @default.
• W2790951009 modified "2023-10-17" @default.
• W2790951009 title "Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)" @default.
• W2790951009 cites W1520609538 @default.
• W2790951009 cites W1985747185 @default.
• W2790951009 cites W2001328643 @default.
• W2790951009 cites W2014561045 @default.
• W2790951009 cites W2101702589 @default.
• W2790951009 cites W2111099202 @default.
• W2790951009 cites W2164089346 @default.
• W2790951009 cites W2165414412 @default.
• W2790951009 cites W2319057797 @default.
• W2790951009 cites W2482008547 @default.
• W2790951009 cites W2512596660 @default.
• W2790951009 cites W2519905430 @default.
• W2790951009 cites W2520424058 @default.
• W2790951009 cites W2531086797 @default.
• W2790951009 cites W2535371675 @default.
• W2790951009 cites W2596179513 @default.
• W2790951009 cites W2916481903 @default.
• W2790951009 cites W4236673002 @default.
• W2790951009 doi "https://doi.org/10.1016/j.amjcard.2017.12.040" @default.
• W2790951009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29472008" @default.
• W2790951009 hasPublicationYear "2018" @default.
• W2790951009 type Work @default.
• W2790951009 sameAs 2790951009 @default.
• W2790951009 citedByCount "16" @default.
• W2790951009 countsByYear W27909510092018 @default.
• W2790951009 countsByYear W27909510092019 @default.
• W2790951009 countsByYear W27909510092020 @default.
• W2790951009 countsByYear W27909510092022 @default.
• W2790951009 countsByYear W27909510092023 @default.
• W2790951009 crossrefType "journal-article" @default.
• W2790951009 hasAuthorship W2790951009A5003094687 @default.
• W2790951009 hasAuthorship W2790951009A5003747242 @default.
• W2790951009 hasAuthorship W2790951009A5008382551 @default.
• W2790951009 hasAuthorship W2790951009A5009467334 @default.
• W2790951009 hasAuthorship W2790951009A5032598384 @default.
• W2790951009 hasAuthorship W2790951009A5052604218 @default.
• W2790951009 hasAuthorship W2790951009A5055380940 @default.
• W2790951009 hasAuthorship W2790951009A5064108235 @default.
• W2790951009 hasAuthorship W2790951009A5066931153 @default.
• W2790951009 hasBestOaLocation W27909510091 @default.
• W2790951009 hasConcept C126322002 @default.
• W2790951009 hasConcept C142724271 @default.
• W2790951009 hasConcept C164705383 @default.
• W2790951009 hasConcept C204787440 @default.
• W2790951009 hasConcept C27081682 @default.
• W2790951009 hasConcept C2776839432 @default.
• W2790951009 hasConcept C2777482532 @default.
• W2790951009 hasConcept C2778163477 @default.
• W2790951009 hasConcept C2779120738 @default.
• W2790951009 hasConcept C2779134260 @default.
• W2790951009 hasConcept C2780072125 @default.
• W2790951009 hasConcept C2780499067 @default.
• W2790951009 hasConcept C2780745583 @default.
• W2790951009 hasConcept C2780902209 @default.
• W2790951009 hasConcept C2780948078 @default.
• W2790951009 hasConcept C2909478654 @default.
• W2790951009 hasConcept C43554185 @default.
• W2790951009 hasConcept C62746215 @default.
• W2790951009 hasConcept C71924100 @default.
• W2790951009 hasConceptScore W2790951009C126322002 @default.
• W2790951009 hasConceptScore W2790951009C142724271 @default.
• W2790951009 hasConceptScore W2790951009C164705383 @default.
• W2790951009 hasConceptScore W2790951009C204787440 @default.
• W2790951009 hasConceptScore W2790951009C27081682 @default.
• W2790951009 hasConceptScore W2790951009C2776839432 @default.
• W2790951009 hasConceptScore W2790951009C2777482532 @default.
• W2790951009 hasConceptScore W2790951009C2778163477 @default.
• W2790951009 hasConceptScore W2790951009C2779120738 @default.
• W2790951009 hasConceptScore W2790951009C2779134260 @default.
• W2790951009 hasConceptScore W2790951009C2780072125 @default.
• W2790951009 hasConceptScore W2790951009C2780499067 @default.
• W2790951009 hasConceptScore W2790951009C2780745583 @default.
• W2790951009 hasConceptScore W2790951009C2780902209 @default.
• W2790951009 hasConceptScore W2790951009C2780948078 @default.
• W2790951009 hasConceptScore W2790951009C2909478654 @default.
• W2790951009 hasConceptScore W2790951009C43554185 @default.
• W2790951009 hasConceptScore W2790951009C62746215 @default.
• W2790951009 hasConceptScore W2790951009C71924100 @default.
• W2790951009 hasIssue "8" @default.
• W2790951009 hasLocation W27909510091 @default.
• W2790951009 hasLocation W27909510092 @default.
• W2790951009 hasOpenAccess W2790951009 @default.
• W2790951009 hasPrimaryLocation W27909510091 @default.
• W2790951009 hasRelatedWork W1595175397 @default.

• next